All Updates

All Updates

icon
Filter
Regulation/policy
DEA considers third extension of telehealth prescribing rules
Mental Health Tech
Oct 15, 2024
Older updates:
Regulation/policy
DEA to plan strict limits on telehealth prescribing of controlled substances
Mental Health Tech
Sep 4, 2024
Funding
BeMe Health raises USD 12.5 million in pre-Series A funding to improve technology
Mental Health Tech
Aug 22, 2024
FDA approval
Big Health receives FDA clearance for SleepioRx digital therapeutic
Mental Health Tech
Aug 14, 2024
Funding
Spring Health raises USD 100 million in Series E funding to support growth plans
Mental Health Tech
Jul 31, 2024
Funding
Headway raises USD 100 million in venture funding, valuing it at USD 2.3 billion
Mental Health Tech
Jul 15, 2024
Product updates
CuraLinc Healthcare launches Mindstream for mental health support
Mental Health Tech
Jul 1, 2024
Funding
Talkiatry raises USD 130 million in Series C funding to expand behavioral health access
Mental Health Tech
Jun 18, 2024
Funding
Marigold Health raises USD 11 million in Series A funding
Mental Health Tech
Jun 18, 2024
Management news
Roy Schoenberg transitions from co-CEO to executive vice chairman of board of Amwell
Mental Health Tech
Jun 13, 2024
Mental Health Tech

Mental Health Tech

Oct 15, 2024

DEA considers third extension of telehealth prescribing rules

Regulation/policy

  • The Drug Enforcement Administration (DEA) has sent a rule titled "Third Temporary Extension of Covid-19 Telemedicine Flexibilities for Prescription of Controlled Medications" to the White House's Office of Management and Budget for review.

  • If approved, this extension would allow healthcare providers to continue prescribing specific controlled substances via telehealth without requiring an in-person visit. The extension could last a year, potentially delaying a decision on permanent rules until the next administration.

  • The DEA previously extended these flexibilities in May and October 2023, with the current extension set to expire at the end of 2024. The potential third extension comes amid ongoing discussions and concerns about the future of telehealth prescribing rules.

  • Analyst QuickTake: Previously, in September 2024 , the DEA was reported to be finalizing proposed rules for prescribing controlled substances via telehealth, which was reportedly more restrictive than advocates hoped. In response, telehealth advocacy groups began gathering signatures for letters to Congress and the White House, as they were uncertain whether the DEA could finalize these rules before flexibilities expired. Given that the DEA is considering extended flexibilities yet again, it seems that the regulatory body is still far from a finalized ruling.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.